MDWD - メディウ―ンド (MediWound Ltd.) メディウ―ンド



symbol MDWD
会社名 Mediwound Ltd. (メディウ―ンド)
分野(sector) Consumer Durables   耐久消費財
産業(industry) Specialty Chemicals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing manufacturing and commercializing therapeutics products in the fields of severe burns chronic and other hard-to-heal wounds connective tissue disorders and other indications. The Company''s product NexoBrid is indicated for the removal of dead or damaged tissue known as eschar in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product EscharEx is a topical biological drug which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.   メディウ―ンドはイスラエルのバイオ医薬品会社。重度熱傷、慢性疾患、その他治癒が困難な創傷、膠原病などの分野で有効な治療法がない医療ニ―ズに対応する製品の開発、製造、商業化に従事する。同社のバイオ医薬品「NexoBrid」は痂皮の切除用製品として、欧州医薬品庁から承認済みである。   MediWound Ltd is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and others.
本社所在地 42 Hayarkon Street Yavne 8122745 ISR
代表者氏名 Stephen T. Wills スティーブン・T・ウィルズ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 8-932-4010
設立年月日 36526
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 76人
EBITDA EBITDA(百万ドル) -12.75100
終値(lastsale) 6.36
時価総額(marketcap) 172857416.04
時価総額 時価総額(百万ドル) 165.24730
売上高 売上高(百万ドル) 2.82000
企業価値(EV) 企業価値(EV)(百万ドル) 138.24330
当期純利益 当期純利益(百万ドル) -14.47300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Mediwound Ltd revenues increased 26% to $1.6M. Net loss decreased 1% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development net decrease of 65% to $1.2M (expense) General and administrative decrease of 40% to $989K (expense).



   Vericel nabs North American rights to MediWound's NexoBrid  2019-05-07
MediWound (NASDAQ: MDWD ) has out-licensed exclusive rights to debridement agent NexoBrid to Vericel (NASDAQ: VCEL ) in North America. More news on: MediWound Ltd., Vericel Corporation, Healthcare stocks news, Stocks on the move, Read more …
   MediWound Ltd. (MDWD) CEO Gal Cohen on Q3 2018 Results - Earnings Call Transcript  2018-11-13
MediWound Ltd. (MDWD) Q3 2018 Earnings Conference Call November 13, 2018 8:30 a.m. ET Executives Monique Kosse - LifeSci Advisors Steve Wills - Chairman of the Board Gal Cohen - President and CEO Sharon Malka - Chief Financial and Operation Officer Analysts Bruce Nudell -…
   MediWound beats by $0.09, misses on revenue  2018-11-13
MediWound (NASDAQ: MDWD ): Q3 GAAP EPS of -$0.11 beats by $0.09 . More news on: Mediwound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more …

 関連キーワード  (医薬品 米国株 メディウ―ンド MDWD MediWound Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)